Cargando…
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxiciti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884912/ https://www.ncbi.nlm.nih.gov/pubmed/31783889 http://dx.doi.org/10.1186/s13045-019-0813-7 |